General
Preferred name
ANIRACETAM
Synonyms
RO 13-5057 ()
Memodrin ()
Ampamet ()
Sarpul ()
1-p-anisoyl-2-pyrrolidinone ()
RO-13-5057 ()
NSC-758223 ()
Draganon ()
RO-135057 ()
P&D ID
PD001087
CAS
72432-10-1
Tags
available
drug
Drug indication
Attention deficit hyperactivity disorder
Cerebrovascular ischaemia
Drug Status
approved
experimental
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Based on this compound's allosteric action on AMPA receptor activity it was used as the structural basis for the development of novel potential ampakines. These compounds are being investigated as nootropics and neuroprotective drugs for the treatment of Alzheimer's disease (AD) and other neurodegenerative conditions (see patent US6730677). (GtoPdb)
DESCRIPTION Based on his compound's allosteric action AMPA receptor activity it was used as the structural basis for the development of novel potential ampakines. These compounds are being investigated as nootropics and neuroprotective drugs for the treatment of Alzheimer's disease (AD) and other neurodegenerative conditions (see patent US6730677).
DESCRIPTION Aniracetam (Ro 13-5057) is an orally active neuroprotective agent, possessing nootropics effects. Aniracetam potentiates the ionotropic quisqualate (iQA) responses in the CA1 region of rat hippocampal slices. Aniracetam also potentiates the excitatory post synaptic potentials (EPSPs) in Schaffer collateral-commissural synapses. Aniracetam can prevents the CO2-induced impairment of acquisition in hypercapnia model rats. Aniracetam can be used to research cerebral dysfunctional disorders[1][2][3][4].
PRICE 29
DESCRIPTION NMDA antagonist; acts glycine site (Tocris Bioactive Compound Library)
DESCRIPTION Increases ion conductance through AMPA glutamate receptors; reported to display;anti-amnesic acitivty (LOPAC library)
DESCRIPTION Desensitization inhibitor (AMPA > kainate) (Tocriscreen Total)
DESCRIPTION Desensitization inhibitor (AMPA > kainate) (Tocriscreen Plus)
DESCRIPTION Aniracetam is a nootropics and neuroprotective drug. (BOC Sciences Bioactive Compounds)
DESCRIPTION Aniracetam (Ro 13-5057)(Ro 13-5057), a nootropic and neuroprotective drug, selectively modulates the AMPA receptor and nAChR. (TargetMol Bioactive Compound Library)
Compound Sets
28
AdooQ Bioactive Compound Library
A10078
BOC Sciences Bioactive Compounds
aniracetam-cas-72432-10-1-item-84-75956
Cayman Chemical Bioactives
17752
ChEMBL Drugs
CHEMBL36994
Concise Guide to Pharmacology 2017/18
4133
Concise Guide to Pharmacology 2019/20
4133
Concise Guide to Pharmacology 2021/22
4133
Concise Guide to Pharmacology 2023/24
4133
Drug Repurposing Hub
DrugBank
DB04599
DrugCentral
221
DrugCentral Approved Drugs
221
DrugMAP
DMOIFW0
DrugMAP Approved Drugs
DMOIFW0
DrugMatrix
EU-OPENSCREEN Bioactive Compound Library
EOS101416
Guide to Pharmacology
4133
LOPAC library
MedChem Express Bioactive Compound Library
HY-10932
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Aniracetam
TargetMol Bioactive Compound Library
T0333
The Spectrum Collection
Tocris Bioactive Compound Library
0867
Tocriscreen Plus
0867
Tocriscreen Total
External IDs
32
Properties
(calculated by RDKit )
Molecular Weight
219.09
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
0
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
1
cLogP
1.46
TPSA
46.61
Fraction CSP3
0.33
Chiral centers
0.0
Largest ring
6.0
QED
0.71
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Ion Channels
Selectivity
AMPA
Pathway
GPCR/G protein
Membrane Transporter/Ion Channel
Neuroscience
Neuronal Signaling
Primary Target
AMPA Receptors
MOA
Inhibitor
glutamate receptor agonist
Target
DRD2, GRIA1, GRIA2, GRIA3, GRIA4, HTR2A
AMPA Receptor-kainate Receptor-NMDA Receptor
iGluR
nAChR
5-HT
dopamine
GluR
Source data